Article
Medicine, General & Internal
Bruce E. Sands, Peter M. Irving, Timothy Hoops, James L. Izanec, Long-Long Gao, Christopher Gasink, Andrew Greenspan, Matthieu Allez, Silvio Danese, Stephen B. Hanauer, Vipul Jairath, Tanja Kuehbacher, James D. Lewis, Edward V. Loftus, Emese Mihaly, Remo Panaccione, Ellen Scherl, Oksana B. Shchukina, William J. Sandborn
Summary: This study evaluated the efficacy and safety of monotherapy with ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease. The results showed that both drugs were highly effective with no significant difference in the primary outcome.
Article
Gastroenterology & Hepatology
Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy
Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Hee Man Kim, Jin Woo Kim, Hyun-Soo Kim, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Won Moon, Sung Hee Jung, Young-Ho Kim, Dong Soo Han
Summary: This study in Korean patients with Crohn's disease found a significant association between the use of azathioprine/6-MP and TNF-alpha antagonists and a reduced risk of abdominal and perianal surgery.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Liang Chen, Zhanjun Lu, Dengfeng Kang, Zhongsheng Feng, Gengfeng Li, Mingming Sun, Zhanju Liu, Wei Wu, Leilei Fang
Summary: This study reveals that ADA significantly improves clinical remission and induces mucosal healing in mildly to moderately active CD patients, and changes in the gut microbiota can be used to predict the efficacy of ADA.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Jin Imai, Hitoshi Ichikawa, Sho Kitamoto, Jonathan L. Golob, Motoki Kaneko, Junko Nagata, Miho Takahashi, Merritt G. Gillilland, Rika Tanaka, Hiroko Nagao-Kitamoto, Atsushi Hayashi, Kohei Sugihara, Shrinivas Bishu, Shingo Tsuda, Hiroyuki Ito, Seiichiro Kojima, Kazunari Karakida, Masashi Matsushima, Takayoshi Suzuki, Katsuto Hozumi, Norihito Watanabe, William Giannobile, Takayuki Shirai, Hidekazu Suzuki, Nobuhiko Kamada
Summary: The study found that in patients with ulcerative colitis (UC) and Crohn's disease (CD), the gut microbiome was more similar to the oral microbiome, indicating increased ectopic gut colonization by oral bacteria in IBD patients. Incipient periodontitis did not significantly affect the clinical outcomes of UC and CD patients, but early periodontitis may be associated with worse clinical symptoms in some CD patients.
Article
Gastroenterology & Hepatology
Anthony Buisson, Stephane Nancey, Luc Manlay, David T. Rubin, Xavier Hebuterne, Benjamin Pariente, Mathurin Fumery, David Laharie, Xavier Roblin, Gilles Bommelaer, Bruno Pereira, Laurent Peyrin-Biroulet, Lucine Vuitton
Summary: This study compared the efficacy of ustekinumab versus azathioprine in preventing postoperative recurrence in Crohn's disease patients. Results showed that ustekinumab was more effective in reducing endoscopic postoperative recurrence rates compared to azathioprine at 6 months.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Medicine, General & Internal
Yanan Wu, Yuyong Tan, Dalian Ou, Xuehong Wang, Yongjun Wang
Summary: This case report highlights a Crohn's disease patient who developed toxoplasma gondii infection after treatment with azathioprine, with a genetic variation in NUDT15 but normal TPMP gene. NUDT15 variation may contribute to reduced tolerance to azathioprine and personalized therapy based on genetic testing may help reduce the risk of adverse events.
Review
Gastroenterology & Hepatology
Evelien M. J. Beelen, Daan Nieboer, Jeanine H. C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio Lopez-Sanroman, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, Annemarie C. de Vries
Summary: This meta-analysis found that anti-TNF-alpha treatment is superior to thiopurine prophylaxis for preventing endoscopic and clinical recurrence of Crohn's disease after ileocolonic resection. This advantage was confirmed in subgroup analysis and after risk stratification.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Bonita Gu, Kavya Venkatesh, Astrid-Jane Williams, Watson Ng, Crispin Corte, Ali Gholamrezaei, Simon Ghaly, Wei Xuan, Sudarshan Paramsothy, Susan Connor
Summary: Maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD. Patients who achieved fistula healing had significantly higher drug trough levels compared to those who did not.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Rebecca Casini, Carrie A. Vyhlidal, Julia M. Bracken, Ashley K. Sherman, Atif Ahmed, Vivekanand Singh, Veronica Williams, Valentina Shakhnovich
Summary: Children with Crohn's disease and duodenal pathology require higher doses of oral azathioprine and have an increased risk of sub-therapeutic drug levels.
Article
Pharmacology & Pharmacy
Leticia Rodrigues de Souza, Daniela Oliveira Magro, Fabio Vieira Teixeira, Rogerio Serafim Parra, Eron Fabio Miranda, Omar Feres, Rogerio Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy, Ligia Yukie Sassaki, Paulo Gustavo Kotze
Summary: Despite some variability in ADA concentrations, higher concentrations are associated with sustained efficacy and low levels can lead to loss of response in CD patients. This study aimed to correlate serum ADA concentrations with clinical and endoscopic activity in CD patients. The results showed no difference in serum ADA concentrations in active or remission CD patients, suggesting no correlation between ADA concentrations and disease activity.
Article
Gastroenterology & Hepatology
Samuel Sassine, Lisa Djani, Christine Cambron-Asselin, Mathieu Savoie, Yi Fan Lin, Marwa Qaddouri, Souhila Zekhnine, Kelly Grzywacz, Veronique Groleau, Martha Dirks, Eric Drouin, Ugur Halac, Valerie Marchand, Chloe Girard, Olivier Courbette, Natalie Patey, Dorothee Dal Soglio, Colette Deslandres, Prevost Jantchou
Summary: Relapse of pediatric Crohn's disease is significantly associated with clinical, endoscopic, histological, and laboratory variables as well as treatment strategies. The relapse rate has decreased over the past decade.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Jiaqi Yao, Xinchan Jiang, Joyce H. S. You
Summary: The study evaluated the cost-effectiveness of proactive versus reactive therapeutic drug monitoring of adalimumab in pediatric patients with Crohn's disease from the perspective of the US health-care provider. Results showed that proactive TDM led to higher quality-adjusted life-years at a lower cost compared to reactive TDM, with ADL drug cost being the most influential factor.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Aurelien Amiot, Jean-Francois Rahier, Filip Baert, Stephane Nahon, Ailsa Hart, Nikos Viazis, Livia Biancone, Eugeni Domenech, Catherine Reenears, Laurent Peyrin-Biroulet, Laurent Beaugerie, Johan Burisch
Summary: This study reports on the impact of the COVID-19 outbreak in patients with inflammatory bowel disease (IBD). The results show that the risk of COVID-19 and severe COVID-19 is not increased in IBD patients compared to the general population. There is also no negative impact of IBD-related medication on the risk of COVID-19 or severe COVID-19. Additionally, the COVID-19 outbreak led to a decrease in endoscopic and imaging procedures, but did not affect clinical activity and treatment.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Francisco Mesonero, Francisco Javier Garcia-Alonso, Maria Jose Casanova, Margarita Fernandez-de la Varga, Fiorella Canete, Luisa de Castro, Ana Gutierrez, Beatriz Sicilia, Victoria Cano, Olga Merino, Ruth de Francisco, Irene Gonzalez-Partida, Gerard Suris, Leyanira Torrealba, Rocio Ferreiro-Iglesias, Beatriz Castro, Lucia Marquez, Ana Sobrino, Ainara Elorza, Xavier Calvet, Pilar Varela, Raquel Vicente, Luis Bujanda, Laura Lario, Noemi Mancenido, Mariana F. Garcia-Sepulcre, Eva Iglesias, Cristina Rodriguez, Marta Piqueras, Juan Angel Ferrer Rosique, Alfredo J. Lucendo, Olga Benitez, Melody Garcia, David Olivares, Carlos Gonzalez-Munoza, Beatriz Lopez-Cauce, Victor Jair Morales Alvarado, Katerina Spicakova, Alicia Brotons, Fernando Bermejo, Pedro Almela, Nahia Ispizua, Pau Gilabert, Carlos Tardillo, Fernando Munoz, Pablo Navarro, Rosa Eva Madrigal Dominguez, Pau Sendra, Esther Hinojosa, Empar Sainz, Maria Dolores Martin-Arranz, Daniel Carpio, Elena Ricart, Berta Caballol, Laura Nunez, Jesus Barrio, Javier P. Gisbert, Marisa Iborra, Margalida Calafat, Vicent Hernandez, Roser Munoz Perez, Jose Luis Cabriada, Eugeni Domenech, Iago Rodriguez-Lago
Summary: This study evaluated the effectiveness of biologic agents in Crohn's disease complicated with internal fistulizing disease. It found that biologic therapy is beneficial for approximately three-quarters of patients, achieving a fistula closure rate of 24%, but around one-third of patients still require surgery. Patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Diego Burgos-Santamaria, Olga P. Nyssen, Antonio Gasbarrini, Dino Vaira, Angeles Perez-Aisa, Luis Rodrigo, Rinaldo Pellicano, Alma Keco-Huerga, Manuel Pabon-Carrasco, Manuel Castro-Fernandez, Doron Boltin, Jesus Barrio, Perminder Phull, Juozas Kupcinskas, Laimas Jonaitis, Inmaculada Ortiz-Polo, Bojan Tepes, Alfredo J. Lucendo, Jose Maria Huguet, Miguel Areia, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, June Ramos-San Roman, Antonio Cuadrado-Lavin, Judith Gomez-Camarero, Manuel Alfonso Jimenez Moreno, Angel Lanas, Samuel Jesus Martinez-Dominguez, Enrique Alfaro, Ricardo Marcos-Pinto, Vladimir Milivojevic, Theodore Rokkas, Marcis Leja, Sinead Smith, Ante Tonkic, Gyorgy Miklos Buzas, Michael Doulberis, Marino Venerito, Frode Lerang, Dmitry S. Bordin, Vincent Lamy, Lisette G. Capelle, Wojciech Marlicz, Daniela Dobru, Oleksiy Gridnyev, Ignasi Puig, Francis Megraud, Colm O'Morain, Javier P. Gisbert
Summary: This study aimed to evaluate the usage, effectiveness, and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe. The results showed that the overall effectiveness of most treatment regimens remained below 90%, and only a few regimens achieved acceptable outcomes in certain cases. Compliance with empirical therapy optimization principles is still poor five years after clinical practice guidelines update.
Review
Gastroenterology & Hepatology
Nurulamin M. Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollon, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S. Ding, Gabriele Dragoni, Federica Furfaro, Patrick F. van Rheenen, Maria Chaparro, Javier P. Gisbert, Edouard Louis, Konstantinos Papamichael
Summary: There is an increasing interest in discontinuing biological treatment for patients with Crohn's disease after a sustained period of remission. Evidence to date suggests that re-treatment with the same biological agent can often regain remission in cases of relapse. The concept of cycling biological therapy may allow a lower therapeutic burden for a subgroup of patients, ensuring disease control with decreased exposure to biological therapy.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Jose Garcia, Maria Chaparro
Summary: For patients with steroid-refractory ASUC, both standard treatment (cyclosporine and infliximab) and newly developed agents (such as vedolizumab and ustekinumab) are effective options.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Maria Jose Casanova, Oscar Nantes, Pilar Varela, Milagros Vela-Gonzalez, Montserrat Rivero, Olivia Sierra-Gabarda, Sabino Riestra, Manuel Barreiro-de Acosta, Maria del Mar Martin-Rodriguez, Carla Jerusalen Gargallo-Puyuelo, Cristina Reygosa, Roser Munoz, Irene Garcia de la Filia-Molina, Andrea Nunez-Ortiz, Lilyan Kolle, Margalida Calafat, Jose Maria Huguet, Eva Iglesias-Flores, Teresa de Jesus Martinez-Perez, Orencio Bosch, Jose Maria Duque-Alcorta, Santiago Frago-Larramona, Manuel Van Domselaar, Victor Manuel Gonzalez-Cosano, Luis Bujanda, Saioa Rubio, Alejo Mancebo, Beatriz Castro, Santiago Garcia-Lopez, Ruth de Francisco, Laura Nieto-Garcia, Viviana Laredo, Ana Gutierrez-Casbas, Francisco Mesonero, Eduardo Leo-Carnerero, Fiorella Canete, Lucia Ruiz, Beatriz Gros, Maria del Moral-Martinez, Cristina Rodriguez, Maria Chaparro, Javier P. Gisbert
Summary: This study compared the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained the adalimumab originator versus those who switched to adalimumab biosimilar. The results showed that switching to adalimumab biosimilar did not show any significant differences in treatment persistence, clinical efficacy, and safety outcomes compared to maintaining the originator.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Dmitry S. Bordin, Irina N. Voynovan, Aiman S. Sarsenbaeva, Oleg V. Zaytsev, Rustam A. Abdulkhakov, Natalia V. Bakulina, Igor G. Bakulin, Marina F. Osipenko, Maria A. Livzan, Sergei A. Alekseenko, Larisa V. Tarasova, Galina N. Tarasova, Pavel O. Bogomolov, Igor V. Maev, Dmitry N. Andreev, Sayar R. Abdulkhakov, Boris D. Starostin, Natalia V. Bakanova, Alla G. Kononova, Sergei V. Kolbasnikov, Elena L. Bueverova, Leticia Moreira, Francis M. Graud, Colm O'Morain, Olga Perez Nyssen, Javier P. Gisbert
Summary: This study evaluated the efficacy and safety of empirical H. pylori furazolidone-containing regimens. The results showed that furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.
TERAPEVTICHESKII ARKHIV
(2023)
Article
Medicine, General & Internal
Cristina Rubin de Celix, Javier Martin-de-Carpi, Gemma Pujol-Muncunill, Laura Maria Palomino, Marta Velasco Rodriguez-Belvis, Rafael Martin-Masot, Victor Manuel Navas-Lopez, Elena Ricart, Maria Jose Casanova, Alejandro Rodriguez-Martinez, Eduardo Leo-Carnerero, Alba Alcaraz, Miriam Manosa, Vicent Hernandez, Maria Consuelo Cobelas Cobelas, Cesar Sanchez, Luis Menchen, Francisco Mesonero, Manuel Barreiro-De Acosta, Nazareth Martinon-Torres, Coral Tejido Sandoval, Alicia Rendo Vazquez, Pilar Corsino, Raquel Vicente, Alejandro Hernandez-Camba, Jose Ramon Alberto Alonso, I. Alonso-Abreu, Ana Maria Castro Millan, Laia Peries Reverter, Beatriz Castro, Estela Fernandez-Salgado, M. Mercedes Busto Cuinas, Jose Manuel Benitez, Lucia Madero, Fernando Clemente, Sabino Riestra, Santiago Jimenez-Trevino, Maia Bosca-Watts, Elena Crehua-Gaudiza, Marta Calvo Moya, Jose Maria Huguet, Ester-Maria Largo-Blanco, Leticia Gonzalez Vives, Rocio Plaza, Ivan Guerra, Josefa Barrio, Laura Escartin, Erika Alfambra, Noelia Cruz, M. Carmen Munoz, Maria Guadalupe Munoz Pino, Manuel Van Domselaar, Belen Botella, David Monfort Miquel, M. Carmen Rodriguez Grau, Agustin De La Mano, Yolanda Ber, Maria Calvo Iniguez, Teresa de Jesus Martinez-Perez, Maria Chaparro, Javier P. Gisbert
Summary: This study evaluated the impact of transition on inflammatory bowel disease (IBD) outcomes and found that transition care programs improve patient outcomes after the transfer from pediatric to adult IBD units. Active IBD at the time of transfer impairs outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Irene Soleto, Cristina Ramirez, Cristina Gomez, Montse Baldan-Martin, Macarena Orejudo, Jorge Mercado, Maria Chaparro, Javier P. Gisbert
Summary: This study reveals that type 2 conventional DCs (cDC2) in patients with inflammatory bowel disease (IBD) exhibit a heightened migratory profile compared to other DC subsets, potentially highlighting new diagnostic biomarkers or immunomodulatory targets for IBD.
Meeting Abstract
Gastroenterology & Hepatology
M. Frasson, T. Pinkney, J. P. Gisbert, I. Rodriguez-Lago, S. Blackwell, K. B. Gecse, C. J. Buskens, C. Knowles, O. Zmora, M. Brookes, G. Fiorino, P. Nos, G. Gallo, F. Pata, A. Verjee, S. Leone, G. Pellino
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. J. Garcia, S. Riestra, A. Amiot, M. Julsgaard, I. Garcia de la Filia, M. Calafat, M. Aguas, L. de la Pena, C. Roig-Ramos, B. Caballol, M. J. Casanova, K. Farkas, T. Boysen, L. Bujanda, C. Cuaran, D. Dobru, F. Fousekis, C. J. Gargallo-Puyuelo, E. Savarino, X. Calvet, J. M. Huguet, L. Kupcinskas, J. Lopez-Cardona, T. Raine, J. Van Oostrom, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, F. Mesonero, R. de Francisco, F. Canete, J. M. Benitez, B. Sicilia, M. D. Martin Arranz, L. de Castro, A. Y. Carbajo, A. Gutierrez, M. Calvo, M. J. Casanova, C. Gonzalez-Munoza, M. Miguel, E. Alfambra, M. Rivero, A. J. Lucendo, C. A. Tardillo, P. Almela, L. Bujanda, M. Van Domselaar, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, M. Piqueras, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado, B. Antolin, P. Ramirez de la Piscina, F. Bermejo, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, M. Chaparro, J. M. Benitez, M. D. Martin Arranz, R. de Francisco, M. Piqueras, L. de Castro, A. Y. Carbajo, F. Bermejo, M. Minguez, A. Gutierrez, F. Mesonero, F. Canete, C. Gonzalez-Munoza, M. Calvo, B. Sicilia, E. Alfambra, C. A. Tardillo, M. Rivero, A. J. Lucendo, L. Bujanda, M. Van Domselaar, P. Almela, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado-Guillena, B. Antolin, P. Ramirez de la Piscina, M. J. Casanova, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)